Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
lundi, octobre 19
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Karyopharm Therapeutics Inc
KPTI
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$0.3901
0.0393
11.2%
Dern. MÀJ: Oct 16, 6:59 PM
$0.3905
0.0397
11.32%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Karyopharm Therapeutics Financials
Karyopharm Therapeutics (KPTI) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M Est
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $133.736 million estimate.
Benzinga Newsdesk
PRO
Karyopharm Therapeutics Q2 EPS $(2.32) Misses $(1.28) Estimate, Sales $33.432M Beat $32.188M Estimate
Benzinga Newsdesk
PRO
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $137.489M Est
Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 million to $130.000 million-$150.000 million vs $137.489 million estimate.
Benzinga Newsdesk
PRO
Karyopharm Therapeutics Q1 EPS $(1.24) Beats $(1.40) Estimate, Sales $35.066M Beat $31.399M Estimate
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.40) by 11.43 percent. This is a 55.23 percent increase over losses of $(2.77) per
Benzinga Newsdesk
Earnings Scheduled For May 14, 2026
Benzinga Insights
PRO
UPDATE: Karyopharm Therapeutics Q4 Adj. EPS $(2.23) Misses $(1.99) Estimate
Benzinga Newsdesk
